



► PHARMA POOL

Dr. Lynn **KRAMER**

EISAI CREATES NEW CHIEF CLINICAL OFFICER POSITION



Eisai, the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has appointed Lynn Kramer, M.D., to the newly created position of chief clinical officer of Eisai Product Creation Systems. In this role, Dr. Kramer is responsible for the approval of protocol designs of pivotal studies to achieve timely regulatory approval of competitive labels for new products, indications and life-cycle extensions. This includes the selection of study regions and clinical sites. He also provides oversight of the design of proof of concept studies for each of Eisai's product creation units.

In addition to these new responsibilities, Dr. Kramer continues to serve as president of the neuroscience and general medicine product creation unit, a position he has held since July 2009. In this capacity, he is responsible for overseeing the full product creation cycle from discovery through regulatory approval of innovative projects.

Dr. Kramer joined Eisai in 2007 as executive VP of global clinical research.

► BIOPHARMA POOL

Dr. Deborah **HARTMAN**

AVAXIA BIOLOGICS APPOINTS VP, RESEARCH



Avaxia Biologics, a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, has appointed Deborah Hartman, Ph.D., as VP, research.

Dr. Hartman is a scientist and senior executive with more than 20 years of experience successfully leading international pharmaceutical research and development functions in multiple therapeutic areas.

Before joining Avaxia, Dr. Hartman held a number of executive level roles at AstraZeneca Pharmaceuticals, most recently as VP of projects in innovative medicines covering lead optimization through early clinical development in infectious diseases.

Dr. Theresa **LAVALLEE**

KOLLTAN PHARMACEUTICALS EXPANDS SENIOR MANAGEMENT TEAM



Kolltan Pharmaceuticals, a privately held biopharmaceutical company, has appointed Theresa LaVallee, Ph.D., as VP, translational medicine.

Dr. LaVallee has more than 25 years of research and industry experience with broad knowledge and proven success in the discovery and development of drug candidates in oncology and inflammation.

Dr. LaVallee most recently served as senior director, translational medicine at MedImmune, the global biologics arm of AstraZeneca.

Dr. Thi-Sau **MIGONE**

IGENICA APPOINTS CHIEF SCIENTIFIC OFFICER



Igenica, an innovative biopharmaceutical company focused on the discovery and development of first-in-class antibody-based therapeutics for the treatment of cancer, has appointed

Thi-Sau Migone, Ph.D., chief scientific officer.

Dr. Migone brings wide-ranging experience in the discovery and development of novel therapeutic antibodies.

Dr. Migone joins Igenica from Human Genome Sciences, where she held a variety of executive positions and most recently served as VP of research.

Dr. Michael **NEEDLE**

ARRAY BIOPHARMA NAMES CHIEF MEDICAL OFFICER



Array BioPharma, a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, has appointed Michael Needle, M.D., as chief medical officer.

Dr. Needle is a board certified hematologist/oncologist and oversees clinical development across Array's pipeline, including its two wholly owned cancer therapeutics, ARRY-520 for multiple myeloma and ARRY-614 for myelodysplastic syndromes, as well as collaborations with strategic partners to advance programs into late-stage development.

► DISCOVERY POOL

Tom **KLEIN**

XOMA APPOINTS CHIEF COMMERCIAL OFFICER



XOMA, which specializes in the discovery and development of therapeutic antibodies, has named Tom Klein to the newly created position of chief commercial officer.

Mr. Klein brings more than 25 years of successful brand commercialization leadership. Mr. Klein joins XOMA from Genentech, where he was VP, business unit head virology and specialty care.

► AGENCY POOL

Liz **BRYAN** Luke **DICKINSON** Rosalba **CANO**

SPECTRUM SCIENCE BOLSTERS SENIOR LEADERSHIP



Spectrum has promoted Liz Bryan and Luke Dickinson to VP and welcomes back Rosalba Cano.



Ms. Bryan and Mr. Dickinson continue to lead key accounts in Spectrum's portfolio of clients focused on consumer products, biopharmaceutical development, and academic research, while assuming greater responsibility for the firm's business and staff development efforts.



Senior healthcare communications professional Ms. Cano rejoined Spectrum, as VP. Ms. Rosalba is charged

with providing counsel to pharma, biotech and nonprofit clients on communications programs and leading scientific communications efforts as well as specific business development efforts.

Kim **COSENZA** Scott **HARPER** Heather **WAGONER** Dr. Dan **ZAKSAS**

DUDNYK PROMOTES SENIOR EXECUTIVES



Four Dudnyk professionals have been promoted to senior positions within the agency.

Kim Cosenza has been promoted to account executive. She has been an integral member of the Dudnyk team since 2011.



Scott Harper, who has been with Dudnyk for five years, has been promoted to VP, account director.

Joining Dudnyk four years ago, Heather Wagoner, has been promoted to account supervisor.

Dan Zaksas, Ph.D., who provides scientific guidance and medical strategy at Dudnyk, has been promoted to VP, scientific director.



► CONSULTING POOL

Terry **STONE**

OLIVER WYMAN NAMES MANAGING PARTNER



Terry Stone has been named to Oliver Wyman's Global Leadership team as the managing partner of the health and life-sciences practice group. She leads the firm's efforts to develop transformational strategies for healthcare companies in the payer, provider, life-sciences, and services and technology spaces.

A partner at Oliver Wyman since 2005, Ms. Stone most recently served as leader of the health services practice.

While there, she worked with major U.S. health plans to devise growth strategies, respond to the healthcare reform world, improve the cost and quality of healthcare services, and establish innovative partnerships across the healthcare sector.

► ASSOCIATION POOL

Drew **HOLZAPFEL**

GLOBAL CEO INITIATIVE ON ALZHEIMER'S DISEASE NAMES EXECUTIVE DIRECTOR

The Global CEO Initiative on Alzheimer's Disease (CEOI) has named Drew Holzapfel, executive direc-



tor. With his addition to the CEOI, Mr. Holzapfel brings a wealth of experience from positions in global and U.S. biotechnology, pharmaceutical, and government organizations to the fight against Alzheimer's disease.

The CEOI is a newly formed private-sector initiative designed to collaborate with the public sector, nonprofit community, and academia, as a response to the call of political leaders for industry to help address this unprecedented global health, societal, and fiscal threat posed by Alzheimer's disease.

Mr. Holzapfel has been in the Alzheimer's and neuroscience fields for more than a decade.

Most recently, he was at Pfizer, where he led commercial strategy efforts around the company's Alzheimer's program.

He also advanced Alzheimer's and aging issues through his work with advocacy with international organizations, non-governmental organizations, nonprofits, and other key stakeholders.

► SERVICE POOL

Dr. Katharine **BATT** Dr. Jay **BHATTACHARYA** Dr. Anupam **JENA**

PRECISION HEALTH ECONOMICS ADDS CLINICAL AND SCIENTIFIC EXPERTS



Precision Health Economics (PHE), a health economics and policy consultancy, has added three scientific leaders to its stable of experts.



The new principal consultants are preeminent researchers and educators representing the most notable institutions in health economics and health policy.



They will contribute to the knowledge base and academic rigor of this growing consultancy of elite thought leaders.

Katharine Batt, M.D., is a clinical fellow in medical oncology, hematology, and palliative care in the department of hematology/medical oncology at Mount Sinai Hospital in New York.

Jay Bhattacharya, M.D., Ph.D., is an associate professor of medicine and a core faculty member at

Stanford University's Center for Health Policy/Primary Care and Outcomes Research.

Anupam Jena, M.D., Ph.D., is an assistant professor of healthcare policy and medicine at Harvard Medical School and an attending physician practicing general inpatient medicine at Massachusetts General Hospital.

Rich **DUDEK** Stephen **GERARD** Gary **MCWALTERS** Sheryl **MORASCO**

TGAS ADVISORS ANNOUNCES LEADERSHIP CHANGES, NEW HIRES



Richard Dudek has joined the TGaS Leadership Team as VP, management advisor, marketing solution, which offers insights and functional assessments related to marketing resources and capabilities. Most recently, he was senior VP, marketing, at Auxilium Pharmaceuticals.




President and Founder Stephen Gerard is stepping back from the day-to-day management of the benchmarking and advisory services firm to become executive VP with a focus on innovation. He will continue to serve as an executive with TGaS Advisors' parent company, KnowledgePoint360.



Gary McWalters succeeds Mr. Gerard as president. V. James Mercante, long-time principal and senior VP, innovations, is retiring.

Mr. McWalters, a 25-year industry veteran, most recently served as executive VP, leading the day-to-day management and commercialization of all TGaS Advisors solutions and headed the marketing advisory practice. Mr. McWalters joined TGaS in 2008 and was responsible for the development and execution of the firm's marketing strategy and tactics.

Sheryl Morasco was named director, management advisor, sales operations. Ms. Morasco, experienced in commercial operations, sales management, customer-facing organizations, and commercial technology, was most recently director, commercial operations at Vivus. 



USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0613-TalentPool



► PHARMA POOL

Marc DUNOYER

ASTRAZENECA APPOINTS EXECUTIVE VP, GLOBAL PORTFOLIO AND PRODUCT STRATEGY

AstraZeneca has named Marc Dunoyer to the role of executive VP, global portfolio and product strategy.

Mr. Dunoyer is responsible for driving business strategy, including business development, mergers and acquisitions, portfolio, and product strategies. His most critical priorities will be to bolster the core growth platforms and therapy areas through well executed business development initiatives and leadership of internal efforts.

Mr. Dunoyer joins AstraZeneca from Glaxo-SmithKline, where as global head of rare diseases, he established an integrated global capability in treatments for rare diseases from R&D through to commercialization.

Richard PASCOE

Apricus Biosciences appointed Richard Pascoe as CEO. Mr. Pascoe brings to Apricus Bio more than 20 years of experience in corporate strategy as well as product development, sales and marketing in the biopharmaceutical industry, and has held positions of increasing responsibility at leading innovative life-sciences companies, including Somaxon Pharmaceuticals, ARIAD Pharmaceuticals, and King Pharmaceuticals.

► BIOPHARMA POOL

Dr. Gregory BERK

BIND THERAPEUTICS NAMES CHIEF MEDICAL OFFICER

Bind Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, has appointed Gregory Berk, M.D. as chief medical officer. Dr. Berk is responsible for leading the company's global clinical development strategy and clinical operations.

Dr. Berk is an oncology veteran with more than 20 years of industry and academic experience. Before joining Bind, Dr. Berk served as chief medical officer of Intellikine, a clinical-stage company developing small molecule drugs targeting signal transduction networks, which was acquired by Takeda Pharmaceutical Company.

Saqib ISLAM

Dr. Martin MACKAY

Dr. Stephen SQUINTO

ALEXION BROADENS AND STRENGTHENS ITS EXECUTIVE LEADERSHIP TEAM

Alexion Pharmaceuticals is broadening its executive leadership team in line with its expanding global mission to develop and commercialize life transforming therapies for patients with disorders that are severe, life-threatening, and ultra-rare.

Saqib Islam has joined Alexion as senior VP, chief strategy and portfolio officer. Mr. Islam has an extensive background in the healthcare banking sector, most recently at Credit Suisse Securities, where he served as managing director.

Martin Mackay, Ph.D., has joined the company as executive VP, global head of R&D. Most recently, Dr. Mackay served as president, research and development at AstraZeneca, where he led all R&D functions on a global basis, including discovery research, clinical development, regulatory affairs, and key related R&D functions.

Stephen Squinto, Ph.D., co-founder of Alexion, has been promoted to the newly created position of executive VP, chief global operations officer. Dr. Squinto continues to serve as a key member of the executive leadership team, having risen to executive VP and head of R&D in 2007.

The arrival of Dr. Mackay and Mr. Islam help to broaden Alexion's portfolio of transformative orphan therapeutic candidates and accelerate the development of these candidates into approved products. The promotion of Dr. Squinto to his new position supports these initiatives and improves and expand critical processes in manufacturing, quality, and corporate project management.

Jodie MORRISON

TOKAI PHARMACEUTICALS APPOINTS CEO

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, has appointed Jodie Morrison to the position of CEO. Ms. Morrison's appointment follows the recent departure of former president and CEO Martin Williams, who has left the company to pursue other opportunities.

Ms. Morrison has held multiple positions of increasing responsibility during her almost seven years at Tokai, most recently serving as chief operating officer and VP, clinical affairs.

Mark ROTHERA

PTC THERAPEUTICS APPOINTS CHIEF COMMERCIAL OFFICER

PTC Therapeutics has appointed Mark Rothera as chief commercial officer. He is responsible for global commercial functions supporting PTC's pipeline, including the investigational new drug ataluren.

Mr. Rothera served previously as global president of Aegerion Pharmaceuticals, where he was

responsible for global commercial operations, manufacturing, and supply chain.

► BIOTECH POOL

Dr. Lee ALLEN

SPECTRUM PHARMACEUTICALS APPOINTS CHIEF MEDICAL OFFICER

Lee Allen, M.D., Ph.D., has been named chief medical officer of Spectrum Pharmaceuticals.

Dr. Allen is a hematologist/oncologist with a strong track record in drug development. He joins Spectrum from AMAG Pharmaceuticals, where he had broad strategic and leadership roles as chief medical officer.

► SPECIALTY POOL

James HUSSEY

SAGENT PHARMACEUTICALS APPOINTS PRESIDENT

Sagent Pharmaceuticals, a specialty pharmaceutical products company with an emphasis on the injectable market, has appointed James Hussey president.

Mr. Hussey has more than 25 years of experience in the pharmaceutical and healthcare industries with experience in both large pharma and emerging start-ups, most recently with Nanolnk, where he served as CEO.

Hong ZHAO

SCICLONE APPOINTS CEO, CHINA OPERATIONS

SciClone Pharmaceuticals appoints Hong Zhao as CEO, China Operations. Mr. Zhao has more than 20 years of experience in leading the commercial operations, market expansion, and growth of multinational companies in China.

Mr. Zhao joins SciClone from Simcere Pharmaceutical Group, a pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, where he served as executive VP, responsible for all business operations, including leading a sizeable sales team and managing multiple business units, and had direct reporting responsibility for medical affairs, market access, marketing and sales operations, training, and personnel development.

► EMERGING POOL

Dr. David EPSTEIN

METASTAT APPOINTS ADVISOR TO LEAD DRUG DISCOVERY

MetaStat, a life-sciences company focused on understanding and treating systemic metastasis, has appointed David Epstein, Ph.D., as advisor for its drug discovery and development efforts.

Most recently he was senior VP and chief scientific officer for OSI Pharmaceuticals, now a wholly owned subsidiary of Astellas, where he had strategic and operational responsibility for small molecule drug discovery and translational research encompassing the company's portfolio of oncology R&D programs.

Kenny FRAZIER
Maryann MURRAY

OPEXA THERAPEUTICS ANNOUNCES CHANGES TO SENIOR MANAGEMENT TEAM

Opexa Therapeutics, which is developing a patient specific T-cell immunotherapy for multiple sclerosis (MS), has strengthened its management team through the appointment of Kenny Frazier as VP of clinical development and regulatory affairs, and Maryann Murray as clinical development manager.

Mr. Frazier was previously at Lexicon Pharma-

ceuticals, where he was a senior director of clinical operations.

Ms. Murray was previously at The University of Texas Health Science Center as a research coordinator.

▶ CONSULTING POOL

Ian FUREMAN
Leigh MCCULLOUGH
Shannon SESA

EVOLUTION MARKETING RESEARCH GROWS ITS PRACTICE WITH KEY ADDITIONS

Evolution Marketing Research, a supplier of insights and intelligence to the healthcare industry, welcomes three new industry professionals. Ian Fureman joins as director, research; Leigh McCullough as associate methodologist; and Shannon Sesa as field coordinator.

Mr. Fureman brings to Evolution more than 14 years of experience in qualitative market research, primarily with clients from the pharmaceutical and biotechnology industries, most recently serving as a principal at Integrated Marketing Associates.

A researcher and statistical analyst with more than 10 years of experience in the pharmaceutical industry, Ms. McCullough most recently served as a biostatistician at ICON Clinical Research, where she provided statistical support for clinical studies, including statistical analyses, data interpretation, and results reporting.

Before joining Evolution, Ms. Sesa held the role of field manager, pharmaceutical market research, at Adelphi Research by Design.

Barbara RYAN

KEY APPOINTMENT BOLSTERS FTI'S HEALTHCARE AND LIFE SCIENCES PRACTICE

FTI Consulting, the global business advisory firm dedicated to helping organizations protect and enhance their enterprise value, has appointed Barbara Ryan managing director of its strategic communications practice.

She joins the firm from Deutsche Bank, where she held the position of managing director and head of the pharmaceutical research team for the past 20 years. In this role, Ms. Ryan published pharmaceutical research, led the firm's annual healthcare conference and conducted extensive marketing activities with institutional clients. **PV**

Searching for the right audience for your next e-mail campaign?

Target PharmaVOICE Readers with your E-mail Marketing Campaign

- Segment our opt-in e-mail database of 65,000+
- 20% off multiple emails
- 50% off all resends
- Best practices for better ROI
- Design and html coding available

Call 215-321-8656 or e-mail mwalsh@pharmavoice.com to discuss your next email promotion with Marah Walsh.

Pharma
VOICE

